ConductScience.org, home

Paper7965656

Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein.

Wasan KM and 3 others. J Pharm Sci, 1994. Cited by 72 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. Papers, record 7965656. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7965656

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein.
PubMed
Journal
J Pharm Sci
PubMed
Year
1994
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
72
iCite
Relative citation ratio, by iCite
2.83
iCite
Revised in PubMed
2019-07-11
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wasan KMK M
2Morton RER E
3Rosenblum MGM G
4Lopez-Berestein GG

Source PubMed

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Amphotericin BMajor topic
Carrier ProteinsMajor topic
Lipoproteins, HDLMajor topic
Animals
Apolipoprotein A-I
Cells, Cultured
Cholesterol Esters
Deoxycholic Acid
Drug Carriers
Humans
Iodine Radioisotopes
Kidney
Kinetics
Lipoproteins, LDL
Liposomes
Receptors, LDL
Surface Properties
Swine

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
HL29582NHLBI NIH HHSUnited StatesP01HL029582PubMed and NIH

Cited by30

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 72 citations.

PMIDTitleJournalYearIn PapersSource
40,243,314Protein-mediated stabilization of amphotericin B increases its efficacy against diverse fungal pathogens.Microbiol Spectr2025https://conductscience.org/library/papers/40243314PubMed
36,411,251Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis.J Antimicrob Chemother2022https://conductscience.org/library/papers/36411251PubMed
36,211,958
Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a Leishmania braziliensis-endemic area.
Front Cell Infect Microbiol2022https://conductscience.org/library/papers/36211958PubMed
31,906,268Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy.Pharmaceutics2020https://conductscience.org/library/papers/31906268PubMed
31,118,866Lipsosomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis.Res Rep Trop Med2019https://conductscience.org/library/papers/31118866PubMed
29,317,800Leishmaniasis in humans: drug or vaccine therapy?Drug Des Devel Ther2018https://conductscience.org/library/papers/29317800PubMed
29,261,103Calli Essential Oils Synergize with Lawsone against Multidrug Resistant Pathogens.Molecules2017https://conductscience.org/library/papers/29261103PubMed
27,855,062Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.Antimicrob Agents Chemother2017https://conductscience.org/library/papers/27855062PubMed
27,697,762Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children.Antimicrob Agents Chemother2016https://conductscience.org/library/papers/27697762PubMed
26,818,726Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.Drugs2016https://conductscience.org/library/papers/26818726PubMed
25,788,110Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF).Drug Deliv Transl Res2011https://conductscience.org/library/papers/25788110PubMed
25,093,386Sub-emetic toxicity of Bacillus cereus toxin cereulide on cultured human enterocyte-like Caco-2 cells.Toxins (Basel)2014https://conductscience.org/library/papers/25093386PubMed
23,703,346Evaluation of toxicity & therapeutic efficacy of a new liposomal formulation of amphotericin B in a mouse model.Indian J Med Res2013https://conductscience.org/library/papers/23703346PubMed
17,722,276Optimizing efficacy of amphotericin B through nanomodification.Int J Nanomedicine2006https://conductscience.org/library/papers/17722276PubMed
15,648,266Unidirectional inhibition of lipid transfer protein I-mediated transfer of cholesteryl esters between high-density and low-density lipoproteins by amphotericin B lipid complex.Pharm Res2004https://conductscience.org/library/papers/15648266PubMed
11,850,269
Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.
Antimicrob Agents Chemother2002https://conductscience.org/library/papers/11850269PubMed
11,850,268Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.Antimicrob Agents Chemother2002https://conductscience.org/library/papers/11850268PubMed
11,741,206Activity and kinetics of dissociation and transfer of amphotericin B from a novel delivery form.AAPS PharmSci1999https://conductscience.org/library/papers/11741206PubMed
11,709,329Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.Antimicrob Agents Chemother2001https://conductscience.org/library/papers/11709329PubMed
11,683,244The effect of serum albumin on amphotericin B aggregate structure and activity.Pharm Res2001https://conductscience.org/library/papers/11683244PubMed

See all 30 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
APOA1335PubTator's text mininghttps://conductscience.org/library/genes/335

Source NCBI Gene

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7965656

GET https://conductscience.org/api/papers/v1/7965656/cited_by?page=2